Page last updated: 2024-12-07

benzoylarginine ethyl ester

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

benzoylarginine ethyl ester: used as substrate for trypsin; RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID123880
CHEMBL ID2323122
SCHEMBL ID80453
MeSH IDM0054675

Synonyms (23)

Synonym
MAYBRIDGE1_005957
benzoylarginine ethyl ester
baee
971-21-1
ethyl (2s)-2-benzamido-5-(diaminomethylideneamino)pentanoate
alpha(n)-benzoyl-l-arginine ethyl ester
l-arginine, n2-benzoyl-, ethyl ester
ethyl-alpha-n-benzoyl-l-arginate
benzoyl-l-arginine ethyl ester
CHEMBL2323122
SCHEMBL80453
ethyl 5-([amino(imino)methyl]amino)-2-(benzoylamino)pentanoate #
n(.alpha.)-benzoyl-l-arginine, ethyl ester
n-.alpha.-benzoyl-l-arginine ethyl ester
AKOS030212152
CCG-251455
DTXSID50914183
n-(5-carbamimidamido-1-ethoxy-1-oxopentan-2-yl)benzenecarboximidic acid
benzoyl arginine ethyl ester
bz-arg-et
EX-A4137
l-arginine,n2-benzoyl-, ethyl ester
PD069703

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The validated HPLC-MS/MS method was successfully applied to the pharmacokinetic study in rats following oral administration of leonurine."( Quantification of leonurine, a novel potential cardiovascular agent, in rat plasma by liquid chromatography-tandem mass spectrometry and its application to pharmacokinetic study in rats.
Cai, W; Ma, G; Sha, X; Shi, X; Zheng, Y; Zhu, Q; Zhu, Y, 2012
)
0.38

Bioavailability

ExcerptReferenceRelevance
" In this article, a leonurine O/O microemulsion (LE-ME) was prepared and investigated for its in vivo pharmacokinetic behavior and bioavailability in the mouse body using an aqueous suspension of leonurine (LE-SWW) for the control group."( A study on the PK and BA profiles in the mouse body for leonurine O/O microemulsion with determination by the LC-MS/MS method.
Ding, Q; Lu, C; Lu, T; Sun, Y; Yuan, Y; Zhang, X, 2016
)
0.43

Dosage Studied

ExcerptRelevanceReference
" Similar dose-response curves for esterase activation, chemotaxis, and chemotactic deactivation were obtained with the chemotactic factor FMLP, suggesting that in human neutrophils all three functions utilize some of the same early molecular events following chemotactic factor binding to th neutrophil surface."( Demonstration of calcium-dependent chemotactic factor activatable esterase activity in human neutrophils: relationship with chemotaxis and chemotactic deactivation.
Kleyman, T; Mandell, B; Mehta, J; Spilberg, I, 1981
)
0.26
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (7)

Processvia Protein(s)Taxonomy
chromatin organizationProtein-arginine deiminase type-4Homo sapiens (human)
nucleosome assemblyProtein-arginine deiminase type-4Homo sapiens (human)
chromatin remodelingProtein-arginine deiminase type-4Homo sapiens (human)
stem cell population maintenanceProtein-arginine deiminase type-4Homo sapiens (human)
protein modification processProtein-arginine deiminase type-4Homo sapiens (human)
post-translational protein modificationProtein-arginine deiminase type-4Homo sapiens (human)
innate immune responseProtein-arginine deiminase type-4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (9)

Processvia Protein(s)Taxonomy
protein-arginine deiminase activityProtein-arginine deiminase type-4Homo sapiens (human)
calcium ion bindingProtein-arginine deiminase type-4Homo sapiens (human)
protein bindingProtein-arginine deiminase type-4Homo sapiens (human)
identical protein bindingProtein-arginine deiminase type-4Homo sapiens (human)
histone arginine deiminase activityProtein-arginine deiminase type-4Homo sapiens (human)
histone H3R2 arginine deiminase activityProtein-arginine deiminase type-4Homo sapiens (human)
histone H3R8 arginine deiminase activityProtein-arginine deiminase type-4Homo sapiens (human)
histone H3R17 arginine deiminase activityProtein-arginine deiminase type-4Homo sapiens (human)
histone H3R26 arginine deiminase activityProtein-arginine deiminase type-4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (5)

Processvia Protein(s)Taxonomy
nucleusProtein-arginine deiminase type-4Homo sapiens (human)
nucleoplasmProtein-arginine deiminase type-4Homo sapiens (human)
cytosolProtein-arginine deiminase type-4Homo sapiens (human)
protein-containing complexProtein-arginine deiminase type-4Homo sapiens (human)
nucleusProtein-arginine deiminase type-4Homo sapiens (human)
cytoplasmProtein-arginine deiminase type-4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID725598Activity of human PAD42013Bioorganic & medicinal chemistry letters, Feb-01, Volume: 23, Issue:3
Novel small molecule protein arginine deiminase 4 (PAD4) inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (105)

TimeframeStudies, This Drug (%)All Drugs %
pre-199040 (38.10)18.7374
1990's30 (28.57)18.2507
2000's15 (14.29)29.6817
2010's20 (19.05)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.63

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.63 (24.57)
Research Supply Index4.72 (2.92)
Research Growth Index4.34 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.63)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (1.80%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other109 (98.20%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]